Drug intelligence / Profile preview

BI 1005273

Development stage: Phase 1
Lead developer: Boehringer
Modality: Small Molecules
Administration: Intravenous, Subcutaneous

Overview

BI 1005273 is a small molecule drug developed by Boehringer Ingelheim GmbH. It has undergone a Phase 1 clinical trial to investigate its safety, tolerability, pharmacokinetics, and early pharmacodynamics in healthy male volunteers. The trial involved intravenous and subcutaneous administration of the drug. The specific therapeutic area or indication for BI 1005273 is not detailed in the available information.

Beyond the preview

Go deeper on BI 1005273.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 1005273.

Explore the full profile